Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lundbeck Places Significant Bet On Myriad Alzheimer’s Candidate Flurizan

This article was originally published in The Pink Sheet Daily

Executive Summary

EU marketing partnership brings Myriad considerable royalties and milestones if compound wins approval as first drug to delay Alzheimer’s progression.

You may also be interested in...



Lundbeck/Myriad Marriage: Short But Not Sweet

Phase III data on Alzheimer’s disease candidate Flurizan comes up short.

Lundbeck/Myriad Marriage: Short But Not Sweet

Phase III data on Alzheimer’s disease candidate Flurizan comes up short.

NTB Measure Gains Ground In Alzheimer's

Investigator in Elan, Lilly and Myriad trials tells “The Pink Sheet” DAILY he is generally optimistic.

Topics

UsernamePublicRestriction

Register

ID1132956

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel